ABSTRACT IL-37 is a cytokine belonging to the IL-1 family. Although discovered in silico in 2000, significant advances in the understanding of its biology were made only in recent years. It is a member of the family with potent antiinflammatory and immunosuppressive properties. It is produced as a precursor without a classic signal peptide. The precursor is cleaved into mature form in the cytoplasm by caspase-1. A small fraction of the cleaved IL-37 binds SMAD-3, translocates to the nucleus, and suppresses transcription of several proinflammatory genes. Both precursor and cleaved forms of IL-37 are secreted. They bind IL-18Ra chain (also used by IL-18 as a receptor subunit) and recruit Toll/IL-1R (TIR)-8 for transducing intracellular signaling. TIR-8 is a member of the IL-1 receptor family (IL-1RF) and was previously known as an orphan receptor. IL-37 suppresses activation of NF-kB and MAPK and activates Mer-PTEN-DOK pathway. It negatively regulates signaling mediated by TLR agonists, proinflammatory cytokines, and IL-1RF ligands. It also affects cell metabolism by inhibiting mTOR, GSK-3a/b, and activating AMPK. Despite having the ability to dampen host's immune responses, the cytokine has been shown to exert antitumor effects, and it has been suggested that it may act as a prognostic marker in a variety of human cancers. Recent studies have suggested that IL-37 may represent a novel therapeutic tool in patients with cancer. In this review, we provide an overview of the cytokine biology, discuss recent advances made in unraveling its anti-cancer effects, and suggest guidelines for future research.
Introduction
IL-37 was discovered in silico more than 16 yr ago; however, we have learned about its biology only in recent years. It turned out to be a member of the IL-1F, with potent anti-inflammatory effects. By inhibiting inflammation, it also exerts significant immunosuppressive, immune deviatory, and metaboregulatory effects. In addition to being expressed in healthy cells and tissues in the body, IL-37 is variably expressed in a variety of cancer cells. Theoretically, it may blunt a host's anticancer immune responses and contribute toward its progression. However, several recent studies have unraveled its host-protective, anticancer effects. They suggest that the cytokine could be used as an important prognostic biomarker as well as a novel therapeutic tool for a variety of cancers (reviewed in Ding et al. [1] ). In this review, we provide an overview of current understanding of the biology of IL-37 and discuss its role as an anticancer agent.
DISCOVERY OF IL-37
IL-37 is a relatively newly discovered member of the IL-1F of cytokines. The family comprises 11 structurally related members, such as IL-1a, IL-1b, and IL-18, among others [2] . All members of the family share a common b-trefoil structure comprising 12 b-strands. IL-37 is a unique member of the family with distinct anti-inflammatory, immune deviatory, immunosuppressive, and metaboregulatory effects [3] [4] [5] . Three research groups discovered it independently in 1999/2000 by searching humanexpressed sequence tag databases and by sequencing the IL-1 gene cluster located on human chromosome 2 [6] [7] [8] . It was given different names like family of IL-1z, IL-1 related protein-1, and IL-1homolog. It turned out that the different names represented different splice variants of the same gene. The gene was designated as the seventh member of the IL-1F (IL1F7), and more recently, it was named as IL37 [9, 10] . Each member of the IL-1 family is produced as a precursor protein, which contains a propiece/prodomain of a variable length. The propiece is removed in the cytoplasm by a protease, thereby rendering the precursor into its biologically active, mature form. Depending on the length of the propiece, IL-1F members are divided into 3 subfamilies: IL-1, IL-18, and IL-33. IL-37 is included in the IL-18 subfamily, which contains only these 2 members. The 2 cytokines are also closely related to each other in their amino acid sequences and 3-dimensional protein structures (reviewed in [3] [4] [5] ). With respect to the IL37 gene, human and mice have undergone divergent evolutionary pathways, probably because of selective pressure from their differential exposures to infections, cancers, and chronic inflammatory diseases. It is the only gene in the IL-1F that is represented by a pseudogene in mice. No functional homolog of human IL37 has yet been discovered in that species.
EXPRESSION OF IL-37
The cytokine is expressed constitutively at low levels in various tissues in the body, including lymph nodes, thymus, bone marrow, intestines, airways, placenta, thymus, uterus, testis, kidney, heart, bone marrow, prostate, and breast, among others [3] [4] [5] 10] . Many cells in the body, including epithelial cells, keratinocytes, renal tubular epithelial cells, monocytes, activated B cells, plasma cells, DCs, macrophages, and CD4 + T reg , have been shown to express IL-37, both in the nucleus and in the cytoplasm [3] [4] [5] [10] [11] [12] . In fact, IL-37 contributes to the immuneattenuating effects of regulatory T and B cells [11, 12] . Despite its widespread expression, healthy humans have ,100 pg/ml IL-37 in their circulation. The half-life of the cytokine mRNA is very short because of the presence of an mRNA instability motif in the coding sequence of exon 5 [13] . Deletion of that exon stabilizes the cytokine transcripts. The motif is responsive to LPS and other TLR ligands, such as lipoteichoic acid, CpG, PAM3CysK4, and flagellin, among others. Treatment of human cells with these ligands stabilizes IL-37 mRNA, by dislodging the mRNAdegrading proteins from the instability motif, and increases expression of the cytokine protein. TLR-induced activation of ERK1/2 and p38 are involved in the mRNA stabilization [13] . Cytokines such as TNF-a, IL-1b, and IL-18, among others, enhance production of IL-37, whereas other cytokines, such as IL-4, IL-12, IL-32, and GM-CSF, among others, have no effect or decrease production of IL-37 [2, 10, 13] . Even IL-37 transgenic mice, in which a constitutively active CMV promoter drives expression of the cytokine gene, express little or no cytokine mRNA unless stimulated by LPS [3, 4] . TGF-b is a major inducer of IL-37 in human cells and tissues [3, 4, 10] , which explains why IL-37 expression is minimal in healthy cells and tissues in the body and increases in inflammatory conditions, such as psoriasis, atherosclerosis, Crohn disease, lupus, and rheumatoid arthritis, among others. Interestingly, LPS induces the IL37 gene transcription in human monocytes concomitantly with those of IL1A and IL1B genes [14] .
ALTERNATE SPLICE VARIANTS OF IL-37 TRANSCRIPTS
The human IL37 gene maps to chromosome band 2q12.21, close to the region where other members of the IL-1F are located. It comprises 3.16-kb DNA, located between the genes for IL-1b and IL-36g, and contains 6 exons [6, 15] . Alternate splicing of precursor mRNA results in 5 splice variants (mRNAs) that are translated into 5 distinct isoforms of the cytokine, named IL-37a-IL-37e. Table 1 shows spliced exons, number of residues, tissue distribution, and potential functions of IL-37 isoforms. Some of the isoforms are expressed in a tissue-specific manner. The largest, most abundant, and most studied of these isoforms is IL-37b. Almost all experimental studies reported in literature have been performed with this isoform, which includes 5 of the 6 exons of the gene (except exon 3). Exons 4-6 are predicted to encode the 12 b-strands that are required for the characteristic b-trefoil structure of the IL-1F members. The isoforms lacking one or more of these exons (c and e) are predicted to encode nonfunctional proteins. Each isoform lacks a typical signal peptide required for secretion. Instead, it contains a prodomain, encoded by the sequences present in exons 1 and 2. The prodomains are cleaved by proteases both intra-and extracellularly [16] . The IL-37a variant lacks exons 1 and 2. It is the only variant that contains exon 3, whose sequences encode a nuclear-localization signal and a cleavage site for catalase. Recombinant IL-37a, with an N-terminus at Lys-27 in exon 4, has been shown to be active [5, 17] . The d-isoform is also predicted to be functional [5] .
PROCESSING OF IL-37
Similar to IL-1b and L-18, IL-37 is produced as a precursor protein with a propiece and no signal peptide. Because of the lack of a signal peptide, the precursor does not enter into the ER and is not secreted via the classic secretory pathway (Fig. 1) . The 218 amino acid precursor of the IL-37b isoform is cleaved in the cytoplasm by activated caspase-1 at residue 20 (Asp) and yields the C-terminal mature form [18, 19] (Fig. 2) . The cleavage site is located in the residues encoded by exon 1. However, evidence for the presence of an alternate cleavage site in the residues encoded by exon 4 has also been presented, which generates a smaller form of the mature IL-37b (amino acids 46-218) that has been detected in the supernatants of IL-37 gene-transfected human embryonic kidney 293 cells. This form shows higher biologic activity than the longer (amino acids 20-218), mature form. It is suspected that a neutrophil-secreted protease generates the smaller form [5, 20, 21] . As shown in Fig. 2 , a third cleavage site in exon 4 has also been predicted to yield the W53-218 mature form. The precursor and mature forms in the human embryonic kidney 293 cells, transfected with the IL-37b cDNA, migrate as 27-and 22-kDa MW bands, respectively, on (continued from previous page) IL-18BP = IL-18 binding protein, IL-1F = IL-1 family, IL-1RF = IL-1 receptor family, KO = knockout, MAD = mothers-against-decapentaplegia in the fruit fly Drosophila melanogaster, MCA = 3-methylcholanthrene, Mer = A receptor tyrosine kinase expressed in monocytes, epithelial, and reproductive tissues, mTOR = mechanistic target of rapamycin, NSCLC = non-small cell lung carcinoma, OSCC = oral squamous cell carcinoma, PAM3CysK4 = the synthetic bacterial lipopeptide Pam3-Cys-Ser-Lys4, PTEN = phosphatase and tensin homolog, PTK-2 = protein tyrosine kinase-2, RCC = renal cell carcinoma, SIGIRR = single immunoglobulin and IL-1R related, siRNA = small interfering RNA, SMAD = a term conjugated from SMA (for SMAll body size in the worm Caenorhabditis elegans), ST-2 = suppressor of tumorigenicity-2, TAK1, TGF-b-activated kinase-1, TIR = Toll/IL-1 receptor-related, VEGF = vascular endothelial growth factor reducing SDS-PAGE [20, 22] . The MW may vary in different cell types, depending on the degree of glycosylation. The precursor and mature forms of IL-37 occur as homodimers in the culture supernatants. Similar to caspase-1, caspase-4 can process the precursor IL-37 into its mature form but with less efficiency, whereas granzymes and other caspases do not cleave the precursor form of this cytokine [18] .
SECRETION OF IL-37
Both the precursor and the cleaved forms of IL-37 are released from the cells via nonclassic secretory mechanisms ( Fig. 1 ) that are not completely understood. Inside the cytoplasm, the cytokine is localized near the plasma membrane, ER, and Golgi apparatus. The localization suggests its release from the plasma membrane via secretory vesicles, despite lacking a signal peptide. The release of the cleaved, but not of the precursor, form from the cells requires activation of caspase-1, which, in turn, depends on the assembly of an inflammasome (reviewed in [3, 4, 19] ). The precursor is also released on cell death and on the loss of membrane integrity. Importantly, about 25% of the cleaved/mature form of IL-37 binds with SMAD-3 in the cytoplasm, translocates to the nucleus, and inhibits transcription of genes for several proinflammatory cytokines and chemokines [19, 22] (Fig. 1) ). SMAD-3 is an SMA-and MAD-related transcriptional regulator involved in TGF-b-mediated signaling [23] .
IL-37 RECEPTOR
The IL-1F cytokines bind members of the IL-1RF. Each member of the IL-1RF usually contains 3 Ig-like domains in the extracellular region for binding its ligand (cytokine) and a TIR domain in the cytoplasmic region for mediating intracellular signals. The structure of a typical member of the family, IL-1RF5, is shown in Fig. 3 . It is also called the IL-18Ra chain. IL-37 has been shown to bind the IL-18Ra chain [4, 18, 24] , which is also used as a receptor component by IL-18. That use was anticipated because the 2 cytokines (IL-18 and IL-37) have similar tertiary structures, and the 2 key residues (Glu-35 and Lys-124), important for binding to the IL18-Ra chain, are conserved in both of them [3, 4] . After binding with IL-18Ra, IL-18 recruits IL-18Rb chain (the seventh member of the IL-1R family or IL1R7) and exerts its proinflammatory effects. Similar to IL-18, IL-37 binds the IL-18Ra chain; however, the complex does not recruit the IL-18Rb chain. It was recently demonstrated that a molecule called TIR-8 acts as the signal-transducing component of the IL-37 receptor [21, 25, 26] (Fig. 3) . TIR-8 has also been named IL-1R8 and SIGIRR. It has been demonstrated that after binding with the IL-18Ra chain, IL-37 recruits TIR-8/IL-1R8/SIGIRR to transduce its anti-inflammatory effects. The tripartite b Number of residues in the precursor form. complex formed by IL-37, IL-18Ra, and TIR-8 assembles on the surfaces of PBMCs, macrophages, and DCs and transduces IL-37-induced signaling. Before those studies, TIR-8 was known as an orphan receptor with no known ligand. Human IL-37 exerts little of its anti-inflammatory effects in TIR-8-deficient human and murine cells. Similar results were observed in vivo in TIR-8 KO mice [21, 25, 26] . TIR-8 was discovered in 1999 [27] . Its gene is located in humans on chromosome band 11p15.5. Interestingly, the genes for other members of the IL-1RF are located on chromosome 2 in humans. TIR-8 is an unusual member of the IL-1RF because it has only 1 Ig domain in its extracellular region compared with the usual 3. Furthermore, it has an unusually long cytoplasmic tail containing an atypical TIR domain (Fig. 3) . Two conserved residues of the conventional TIR domain (Ser-447 and Tyr-536) are replaced by Cys-222 and Leu-305 in the TIR domain of TIR-8. Therefore, TIR-8 cannot recruit TIR domain-containing adaptor molecules for signal transduction. Instead, TIR-8 dampens TLR-and IL-1R-stimulated signaling [27; reviewed in 28]. Although the exact molecular mechanisms are not known, they may involve interference with dimerization of TIR domaincontaining adaptor molecules and/or their recruitment to the receptor complexes, which are required for the TLR-and IL-1R-induced signaling. Consequently, TIR-8 KO murine and human cells are hyperresponsive to TLR agonists and IL-1F cytokines. They produce abundant proinflammatory cytokines and chemokines upon treatment with LPS [28, 29] . In fact, TIR-8 can also dampen IL-33-mediated Th2-type responses [30] . TIR-8 forms complexes with ST2, the receptor for IL-33, and inhibits cytokine-mediated signaling [30] .
TIR-8 is expressed on a variety of cells and tissues in the body, including DCs, T and B cells, NK cells, neutrophils, macrophages, neurons, astrocytes, microglia, and epithelial cells of the airways, gastrointestinal tract, and renal tubules, among others [28] . Interestingly, inflammatory stimuli, which stabilize IL-37 mRNA and increase IL-37 production, down-regulate the expression of TIR-8 on human and murine cells. They do so by activating p38 and preventing binding of specificity protein 1 to TIR-8 promoter [31] . Chemical inhibitors of p38 (e.g., SB203580) prevent this down-regulation.
The modulation of TIR-8 expression has implications in human pathophysiology. For example, a down-regulation of TIR-8 by amyloid-b via induction of TLR-2 on the microglia in the human brain has been implicated in the development of Alzheimer disease [2, 5, 31] . In contrast, TLR activation induces expression of TIR-8 on DCs from Peyer patches and provides tolerance to gut-dwelling bacteria [28, 32] . Induction of TIR-8 is one of the mechanisms by which the probiotic Lactobacillus jensenii induces tolerance in porcine APCs [33] . Decreased expression of TIR-8 on intestinal epithelial cells in necrotizing enterocolitis in neonates has been implicated in progression of the disease [34] . The existence of a dominant, negative, exon-8-deleted, splice variant of TIR-8 was recently shown to have a role in inflammation of the gastrointestinal tract and the development of colitis-induced CRC in humans and a mouse model [35] (see more below).
IL-37-INDUCED SIGNALING
In contrast to other members of the IL-1F, IL-37 is unique in exerting anti-inflammatory effects. Transcriptomic-and proteomic-based analyses of IL-37 transgenic and TIR-8 KO mice have shown that the anti-inflammatory effects of the cytokine are mediated by 2 different mechanisms ( Fig. 3 ) [25] . The first mechanism is based on its binding with the IL-18Ra/SIGIRR. Both the precursor and the mature cleaved forms of IL-37 are biologically active; however, the mature form binds the receptor more efficiently than the precursor form does. The second mechanism is based on SMAD-3, a member of the SMAD family of transcription factors/regulators that transduce TGF-b1-mediated signals [23] . As mentioned, a fraction of the caspase-1-cleaved IL-37 in the cytoplasm binds SMAD-3 and translocates to the nucleus, where it inhibits transcription of several proinflammatory genes, such as TNF-a, IL-6, among others (Fig. 3) [19, 22] . Earlier studies had identified IL-37 as a binding partner for SMAD-3 [36] ; however, the significance of that partnership was not appreciated until recently. Notably, mutant IL-37, which cannot be cleaved by caspase-1, does not bind SMAD-3 and translocate to the nucleus [22] .
The 2 IL-37-activated signaling pathways work in parallel and in synergy to broaden the profile of the anti-inflammatory effects of the cytokine. The binding of IL-37 to its receptor activates the Mer-PTEN-FOXO-STAT-3 and p62 (DOK-1) cascade, and inhibits Fyn and TAK1 kinases upstream of NF-kB and MAPK. The DOK family members are well known as negative regulators of various immunoreceptor-mediated, activating, signaling cascades [37] . The effects of STAT-3 activation are dependent of context because its activation by IL-10 prevents, and by IL-6 promotes, polarization of macrophages into the proinflammatory M1 phenotype [38] . The signaling pathways culminate in the inhibition of NF-kB, PI3K, MAPK, TAK1, mTOR, inflammasome assembly, TLR, and IL-1RF-mediated activation signals and the activation of PTEN, STAT-3, and AMPK [3, 4, 25, 28, 39] . It was demonstrated in murine and human macrophage cell lines and in vivo studies that SMAD-3 siRNA and SMAD-3 inhibitors cause significant reductions in the anti-inflammatory effects of human IL-37 [3, 10, 19] . The cytokine-induced inhibition of spleen tyrosine kinase and Ca ++ -dependent tyrosine kinase is exclusively mediated by SMAD-3 and does not require signaling via the cytokine receptor IL-18Ra/TIR-8 [10, 28] . Ca ++ -dependent tyrosine kinase has been implicated in monocyte spreading and motility. The cytokine-mediated inhibition of the phosphorylation of STAT-1, STAT-4, p38, and GSK-3a/b is also mediated via SMAD-3. The neutralization of the secreted IL-37 with IL-37-neutralizing Abs significantly (2.5-fold) increases cytokine response to LPS in IL-37 transgenic mice. These results suggest that, at least in transgenic mice, the secreted cytokine has a more-important role in inhibiting responsiveness to LPS [10, 28, 40] . The pathways may vary in different cell types, depending on their milieu, context, and differentiation state, among others.
BIOLOGIC EFFECTS OF IL-37
The main biologic effects of IL-37 are summarized in Table 2 . The cytokine represents a fundamental inhibitor of innate and adaptive immune responses. These effects essentially derive from the anti-inflammatory actions of the cytokine [3, 5] . The cytokine inhibits production of IL-6, TNF-a, IL-1, and others, from LPS-activated human PBMCs in picomolar concentrations. Similar inhibitory effects are observed upon activation with other TLR ligands as well as with IL-1RF ligands. Furthermore, IL-37 also inhibits assembly and activation of inflammasomes and, hence, production and maturation of proinflammatory cytokines, such as IL-1b and IL-18 [5, 39] . The down-regulation of IL-37 synthesis by siRNA in human PBMCs and macrophages leads to increased production of several proinflammatory cytokines (e.g., IL-1R antagonist, IL-1a, IL-1b, IL-18, IL-6, IL-12, IL-23, IL-17, G-CSF, GM-CSF, and TNF-a, among others) and chemokines (e.g., MIP-2/CXCL2, BLC/CXCL13, and IL-8/CXCL8, among others) [3, 4, 22, 39] . The cytokine, however, has no, or only minimal, effects on the secretion of IL-10 and TGF-b. Similar changes in cytokine and chemokine secretions were seen in human intestinal and airways epithelial cells upon IL37 gene silencing. Furthermore, administration of IL-37-neutralizing Ab to humans in vivo caused increased production of proinflammatory cytokines from their PBMCs [21] . The adherent cells in the PBMCs of the Ab recipients differentiated into the proinflammatory M1 phenotype. The cytokine inhibits LPS-induced production of proinflammatory cytokines from macrophages and causes a decrease in p38, ERK1/2, and JNK phosphorylation [21] . Forced expression of the IL37 gene in human THP-1 cells causes reduced expression of FAK, PTK-2, and paxillin and decreased cell migration and adhesion. It also decreased expression of Hck, mTOR, and p53 in these cells [21] . IL-37 has also been shown to inhibit LPS-induced vacuolization, cause the formation of pseudopodia, and increase motility in these cells [3, 10, 21] . Similar to macrophages, human epithelial cells respond poorly to inflammatory stimuli upon forced expression of the human IL37 gene [10, 16] . As mentioned, no IL-37 equivalent cytokine has been found in mice; however, when human IL-37 was overexpressed in murine, macrophage-like RAW cells, they became hyporesponsive to LPS and produced fewer proinflammatory cytokines [10] . These results suggest that human IL-37 is functional in murine cells. In line with these observations, the mice expressing human IL-37 as a transgene were relatively resistant to the DSS-induced colitis, [56]
7.
Inhibition of mTOR and GSK-3b, activation of AMPK, and causation of pseudostarvation [10, 57] 8.
Induction of tolerance to gutdwelling commensal bacteria [55] concanavalin A-induced hepatitis, ischemia-reperfusioninduced renal and myocardial injuries, and contusion-induced spinal cord injury. These mice are also relatively resistant to LPS-induced toxemia [41] [42] [43] [44] [45] . The IL-37 transgenic mice, however, are apparently normal and exhibit reduced inflammatory and immune responses to model Ags and pathogens. Furthermore, recombinant human IL-37 protects mice from ovalbumin-induced allergic asthma and airway hyperresponsiveness. The protection depended on the presence of TIR-8 in the mice [5, 26] . However, the house dust mite and cockroach allergen-induced airway inflammation was reduced in the TIR-8 gene KO mice probably because of the innate ability of the mice to increase Th1-type, but not of Th2-type, immune responses [46] . Over all, IL-37 is a general inhibitor of immune responses and attenuates Th1, Th2, and Th17 responses [3-5, 26, 46, 47] . It inhibits LPS-induced maturation of DCs and renders them tolerogenic. Such DCs deviate Ag-induced immune responses toward the generation of T regs . Consistent with these results, the DCs from IL-37 transgenic mice have impaired capacity for maturation and produce more IL-10. Not surprisingly, hapteninduced contact hypersensitivity was effectively suppressed in the IL-37 transgenic mice [3, 5, 48] . Because of its ability to promote Ag-specific T regs , IL-37/TIR-8 system has an important role in peripheral tolerance and a protective role against the development of autoimmune diseases [49] .
In sharp contrast with IL-37 transgenic mice, TIR-8 KO mice show exacerbated responses in their models of asthma, neuroinflammation, and spinal injury, suggesting a protective role of the cytokine in these pathologic conditions [26, 45, 50] . The IL-37/TIR-8 system has a dual role in bacterial and fungal infections. On one hand, it attenuates the resistance of mice to these pathogens. On the other hand, the system also reduces inflammation and pathology in those infections. The cytokine decreases resistance of mice to Streptococcus-induced pneumonia and sepsis. Consistent with those results, TIR-8 KO mice display lower bacterial growth and dissemination in their bodies and decreased mortality. Their macrophages exhibit enhanced phagocytosis [51] . The absence of TIR-8 has also been shown to provoke exaggerated local and systemic inflammatory responses, pathology, and mortality in Pseudomonas aeruginosa infections of lungs in mice [52] . Similarly, IL-37 prevents activation of inflammasomes and pulmonary pathology from nonresolving aspergillosis in mice in as small a dose as 1 mg per animal [53, 54] . The expression of TIR-8 on intestinal epithelial cells in the gut dampens antimicrobial responses and promotes tolerance to the gut-dwelling commensals. In TIR-8 KO mice, because of excessive antibacterial responses, commensal populations decrease and make the mice more susceptible to pathogenic, colitisinducing bacteria, such as Citrobacter rodentium and Salmonella typhimurium, among others [55] .
In addition to its anti-inflammatory and immune-deviatory effects, IL-37 also exerts metabolic effects on the cellular and organismal levels. IL-37 transgenic mice are resistant to the metabolic effects (acidosis, hypothermia, dehydration, hyperkalemia, and liver damage, for example) caused by a sublethal dose of LPS. The transgenic mice are also relatively less susceptible to obesity-induced inflammation and insulin resistance [56] . They show reduced infiltration of macrophages in their adipose tissue as well as enhanced levels of adiponectin in their circulation. In vitro, IL-37 activates AMPK in adipocytes and reduces adipogenesis. Furthermore, expression of the cytokine gene in adipose tissue correlates inversely with its inflammatory status [56] . The cytokine inhibits mTOR and GSK-3a/b and activates AMPK, causing pseudostarvation [3, 25, 57] . In this regard, its effects are akin to metformin. The cytokine, therefore, may be useful against metabolic syndrome. Considering the diverse array of its biologic effects, it is tempting to speculate that IL-37 may bind additional unknown receptor components and/or transcription factors in human and murine cells.
IL-37, IL-18, AND IL-18BP
IL-18Ra chain is the ligand-binding component for IL-37 and IL-18 receptors. Under physiologic conditions, IL-37 is unlikely to compete with mature IL-18 for binding with that chain because its affinity for the chain is 50 times less than that of IL-18 [18] . IL-18BP, a naturally occurring, high-affinity antagonist of IL-18 and a member of the Ig superfamily, also binds IL-37 and regulates its anti-inflammatory effects. Its affinity is, however, much greater for IL-18 than for IL-37. IL-37 increases the inhibitory effects of IL-18BP for IL-18 [58] . However, subsequent studies have shown that, at lower and medium concentrations, IL-18BP preferentially neutralizes IL-18 and ameliorates disease severity in mice with collagen-induced arthritis, but, at higher concentrations, it also counters the anti-inflammatory effects of IL-37 and loses its beneficial effects [59, 60; reviewed in 61]. These results suggest that IL-18BP can antagonize both IL-18 (a proinflammatory cytokine) and IL-37 (an anti-inflammatory cytokine). It was anticipated that IL-18BP could be used as a therapeutic tool in IL-18-mediated inflammatory diseases. These findings, however, suggest caution because it could also abrogate the anti-inflammatory effects of IL-37. Conversely, IL-18BP may bind and accentuate the anti-inflammatory effects of IL-37 [3, 5] . Clearly, the issue requires further investigations.
ROLE OF IL-37 IN CANCER
In addition to expression in healthy tissues, the cytokine is also expressed at both mRNA and protein levels in cancer cells, such as U937, THP1, Raji, A431, HL-60, KG1, and HPT4; melanoma; and colon and breast cancer cell lines but not in prostate cancer cell lines [3, 4, 10, 18] . Similar to what was found in healthy cells, cytokine expression is enhanced in cancer cells upon treatment with LPS and other TLR ligands. Because TIR-8 has the only recently been known to act as a component of the IL-37 receptor, earlier studies investigated the role of TIR-8 in the development of cancer without any reference to IL-37.
A PROTECTIVE ROLE FOR TIR-8 IN MALIGNANCIES
Since the IL-37/TIR-8 system dampens inflammation, the system was predicted to provide protection from the cancers in which inflammation has a role. For example, the expression of TIR-8 has been shown to have a protective role in colitis-associated cancer. TIR-8 KO mice were more susceptible to azoxymethaneand DSS-induced, colitis-associated colorectal cancers, a model mimicking CRC occurring in patients with chronic inflammatory bowel disease [62, 63] . The mutant mice developed morenumerous, bigger, and more-severe lesions than wild-type mice. Furthermore, forced expression of the TIR-8 gene in intestinal epithelial cells abrogated susceptibility of the TIR-8 KO mice to the colitis-associated cancer, suggesting the involvement of intestinal-specific TIR-8 in cancer development [63] . The loss of the TIR-8 gene also promotes intestinal cancer in APC +/2 mice, a model for familial adenomatous polyposis syndrome [64] . In those cancers, TIR-8 exerts its antitumor role by dampening inflammation and by inhibiting mTOR activity and, consequently, inhibiting cell cycle progression and genetic instability [63] . To evade antitumor effects, cancer cells down-regulate expression of TIR-8 on their surface and/or express a functionally defective splice variant that lacks exon 8 [35] . The exon 8 of TIR-8 is a "weak exon" with a high probability of exclusion. The architectural protein CCCTC-binding factor, which coordinates genome topology with transcription and favors inclusion of weak exons into mRNA, binds cognate sequences in exon 8. When these sequences are methylated, the CCCTC-binding factor is abrogated, which promotes exclusion of this exon. Cancer cells promote expression of the exon 8-deleted TIR-8 mutants by hypermethylation. Consistent with that, treatment of cancer cells with decitabine, a methyltransferase inhibitor, increases expression of wild-type TIR-8. Exon 8-derived amino acid sequences bear 4 N-linked glycosylation sites. The exon 8-deleted mutant protein, therefore, has reduced N-glycosylation and is predominantly retained in the ER [35] . It is also functionally dominant because it binds the Wilms tumor protein and retains it in the ER. Two mechanisms underlying the action of the exon 8-deleted TIR-8 have been proposed: 1) the lack of modifications by complex glycans may unmask an Argbased ER retention motif, and/or 2) the mutant protein may bind ribophorin-1, a subunit of the ER-resident N-oligosaccharyltransferase complex, and inhibit N-linked glycosylation. The cancer cells expressing the mutant TIR-8 have greater proliferative capacity and express more Bcl-XL and cyclin D1. They also chemoattract and recruit more T regs and Th2-type CD4 + T cells in the cancer microenvironment, which leads to increased concentrations of immunosuppressive cytokines, such as IL-10 and TGF-b, in the tumor microenvironment [35; reviewed in 28] . It was recently reported that CRC cells in humans express the exon 8-deleted variant, and the cancer cells almost act as TIR-8-deficient cells [35] .
In addition to intestinal cancers, SIGIRR was also implicated in hematologic malignancies. For example, malignant B cells in patients with CLL express reduced levels of the TIR-8 mRNA as compared to healthy human B cells. In the Em-TCL1 transgenic mouse (a transgenic mouse model expressing the transcription factor TCL1 under the control of a VH promoter-IgH-Em) model of CLL, the loss of the TIR-8 gene triggers CLL earlier and in a more-aggressive form and reduces the life span of the mice [65] . Consistent with its anti-inflammatory effects, IL-37 was shown to inhibit age-induced inflammation and B cell leukemogenesis and to increase the life span in the mice [66] . The role of TIR-8 in the development of intestinal and hematologic malignancies implies a potential role for its recently recognized ligand (IL-37) in human cancers.
Given the immunosuppressive and immune-deviating effects of IL-37, the cancer cells are thought to produce it to dampen the host's anticancer responses. Conversely, the protective role of the cytokine in the development of diverse types of human cancers has been described ( Table 3 ) and are discussed next.
Fibrosarcoma
The earliest report concerning the protective role of IL-37 in cancer came in 2003 [67] in fibrosarcoma, a malignant tumor derived from mesenchymal fibroblasts. The investigators used the MCA-induced murine fibrosarcoma cell line MCA205. They showed that a single intratumor injection of a recombinant adenovirus expressing the human IL37 gene (IL-1H4, which encodes the IL-37b isoform) caused regression of intradermally established fibrosarcoma in C57BL/6 mice. Multiple injections of the virus completely inhibited tumor development in the mice. The IL-37-treated mice also developed cancer-specific immunity and became resistant to a rechallenge with larger doses of the cancer cells injected at a different site. The virus, however, failed to protect against the cancer in B6.Cg-Foxn1 nu nude and B6.CB17-Prkdcscid/SzJ SCID mice, indicating that T and B cells were needed for the protection because these immunodeficient mice lack T and B cells. Furthermore, no effect was observed in FasL-, IL-12-(p40), or IFN-g-deficient mice. Interestingly, the protective effect of the cytokine was maintained in NKT-deficient mice [67] . The researchers also reported no differences in the numbers and types of tumorinfiltrating lymphocytes in the tumors treated with the recombinant virus and the control virus-treated tumors. Given the inhibitory effect of the cytokine on the production of a range of cytokines, results were quite unexpected. The authors did not verify expression of IL-37 in the established tumors. Therefore, the anticancer effects could have been caused simply by an antiviral immunity and not by IL-37.
Cervical cancer
A study in 2015 [68] reported antitumor effects of the cytokine against cervical cancer. The authors showed that the cytokine gene transfection with an expression plasmid inhibited the proliferation and invasiveness of both HPV + (HeLa) and HPV
2
(C33A) cancer cell lines [68] . The inhibitory effect was more pronounced in HPV + cells. Chronic inflammation from chronic HPV infections has a crucial role in the development of cervical cancer [69] . The cytokine decreased the expression of mRNA and protein as well as the phosphorylation of STAT-3 in the cancer cells. The STAT-3 siRNA abrogated the cytokine's protective effects. The IL37 gene transfection into cancer cells also reduced production of proinflammatory cytokines IL-1b and TNF-a from the cancer cells. The study showed that the anticancer effects of IL-37 could be explained by its inhibitory effects on the production of proinflammatory cytokines, which are known to act as growth factors in cancer cells and represent one of the mechanisms by which inflammation promotes carcinogenesis [70, 71] , and inflammation is one of the hallmarks of cancer [72] .
HCC
HCC results from chronic liver inflammation caused by hepatotropic viral infections from hepatitis C and hepatitis B viruses, aflatoxin exposure, or alcoholism. The cancer develops in inflammatory and fibrogenic microenvironment fueled by proinflammatory cytokines. Zhao et al. [73] investigated the anticancer effects of IL-37 in HCC. The authors examined 163 clinical samples of primary HCC for intratumoral IL-37 expression. They found that the level of cytokine expression correlated negatively with the cancer size. Importantly, greater expression of the cytokine within the tumors correlated with better prognosis, judged by overall and disease-free survival of the patients with HCC. They also observed that cytokine expression was decreased in the cancer, whereas its expression was nearly normal in surrounding healthy liver tissues. The cytokine expression in the cancer also correlated with higher infiltration of CD57 + NK cells but not with CD3 + CD8 + T lymphocytes. The expression of CD57 on NK and T cells represents a mark of their functional maturity [74] . The investigators also showed that the IL37 gene-transfected cancer cells chemoattracted NK cells in vitro as well in vivo in mice. NK cells express the IL-18Ra chain as well as TIR-8, the 2 components constituting the receptor for IL-37 [3, 28] . The study suggested, for the first time, a chemotactic role for the cytokine in NK cells. Another study [75] showed that the cytokine inhibited growth, migration, and invasiveness of an HCC cell line (SMMC-7721) in vitro. The mechanisms involved inhibition of STAT-3 phosphorylation and production of matrix metalloproteinase-2 [75] . The studies suggest that expression of IL-37 in HCC may be used as a prognostic biomarker as well as a therapeutic tool.
RCC
Jiang et al. [76] investigated the role of IL-37 in RCC. They found that cytokine concentrations in the circulation were decreased in patients with RCC compared with healthy individuals and correlated inversely with the size and stage of the cancer. In vitro, recombinant human IL-37 induced apoptosis and decreased survival and migration of the 2 RCC cell lines A498 and Caki-1. IL-37 inhibited the induction of IL-6 and the activation of STAT-3 (phosphorylation at Tyr-705) in the cancer cells. The expression of STAT-3-targeted genes-HIF-1a, Bcl-2, and cyclin D1-was also reduced. IL-6 gene transfection abrogated the cytokineinduced inhibition of STAT-3 activation in the cancer cells. The recombinant cytokine also reduced tumor size and increased survival of SCID mice xenografted s.c. with the renal cancer cells by decreasing expression of IL-6 and HIF-1a. HIF-1a is known to promote angiogenesis and glucose uptake in cancer cells, and its expression correlates with a poor prognosis in patients with RCC [77] . The mechanism for the protective effects of IL-37 in RCC seems to be similar to that described above in cervical cancer [68] .
NSCLC
Ge et al. [78] recently reported anticancer effects from IL-37 in NSCLC. They showed that IL37 gene transfection in a lung cancer cell line (H1299/1169) had no effect on the growth and proliferation of the cells. However, when implanted in nude mice, the cytokine gene expression reduced cancer growth. The cytokine inhibited expression of VEGF, a well-known angiogenic and vasculogenic factor [79] . In vitro, the cytokine inhibited growth of, and tube formation from, human umbilical vascular endothelial cells. Furthermore, expression of IL-37 correlated inversely with tumor microvessel density. The authors found no difference in the in vivo infiltration of DX5 + NK cells, CD11c + DCs, and CD11b + macrophages in the IL-37-expressing and not-expressing, freshly isolated tumors from human patients. Interestingly, IL-37 was also shown to induce pathologic angiogenesis in the context of hypoxia [80] . The hypoxia-induced expression of IL-37 in vascular endothelial cells promoted cell proliferation, capillary formation, migration, and vessel sprouting from aortic rings. The cytokine also promoted vessel growth in implanted matrigel plugs in vivo in a dose-dependent manner. Thus, the inhibitory effects of the cytokine on angiogenesis in NSCLC may be dependent on context. As mentioned for HCC, IL-37 may serve as an important prognostic marker and a useful therapeutic tool for patients with NSCLC.
OSCC
Lin et al. [81] studied that role of IL-37 in OSCC. They demonstrated that IL-37 expression followed a wave-curve pattern in the development of this cancer, that is, expression NSCLC Decreased production of VEGF; decreased angiogenesis [78] Breast cancer (murine model) Activation of CD4 + T cells; alteration of tumor microenvironment [82] OSCS Decreased migration and metastasis [81] increased from healthy oral keratinocytes to precancerous lesions, and then, decreased from precancerous lesions to the development of the cancer. Oral leukoplakia is a precancerous lesion in this cancer, and oral leukoplakia with epithelial dysplasia showed greater expression than oral leukoplakia without epithelial dysplasia. The expression of the cytokine colocalized with the cytokine receptor subunit IL-18Ra chain but not with IL-18BP. Importantly, the expression was greater in nonmetastatic OSCC than it was in metastatic OSCC. The OSCC cell line with greater IL-37 expression showed decreased migratory potential [81] . The authors concluded that the cytokine protected the host by decreasing the metastasis of the cancer cells.
Breast cancer
As mentioned, expression of IL-37 is increased in human breast cancer cell lines [18] . No study has, so far, to our knowledge, reported on the role of IL-37 in breast cancer in women. However, the role of IL-37 was investigated recently in mice using a breast cancer cell line, 4T1, model [82] . When the human IL37 gene was transduced in the cancer cells using a recombinant adenovirus, the cytokine was produced and secreted from the cells. However, the IL37 gene transduction had no effect on the proliferation of cancer cells in vitro. The IL-37-expressing 4T1 cancer cells grew into smaller tumors when they were transplanted in mammary fat pads in immunocompetent, but not in immunodeficient (nude and NOD-SCID), BALB/c mice. Despite smaller tumors, no effect of the gene transduction was observed on animal death and tumor metastases. The study also showed that in vitro IL-37 caused activation and proliferation of CD4 + , but not of CD8 + , T cells. These activated CD4 + T cells may have prevented growth of the cancer cells in vivo in mice. However, no experimental proof was provided. The antitumor effects of IL-37 seem to be similar to those reported above for fibrosarcoma [67] . In the 2 studies, the IL37 gene was transfected in cancer cells using recombinant adenoviruses, and the antitumor effects of the cytokine seem to be mediated by enhanced T cell functions.
MECHANISMS OF IL-37-MEDIATED ANTICANCER EFFECTS AND UNANSWERED QUESTIONS
The studies conducted to investigate the role of IL-37 in human cancers strongly suggest host-beneficial, protective effects of the cytokine for patients with cancer. The cytokine employs a variety of anticancer mechanisms, including chemotaxis of certain immune cells and inhibition of STAT-3 activation, angiogenesis, cell migration, and cell invasiveness (summarized in Table 3 ).
STAT-3 is a transcription factor that promotes cell proliferation and inflammation [83] . IL-37 was reported to inhibit its activation directly in transgenic mice [25] . The cytokine also inhibited it indirectly by inhibiting the production of proinflammatory cytokines such as IL-6 that induce STAT-3 activation. It would be interesting to investigate the role of the suppressor of cytokine-signaling proteins that prevent activation of STATs by various cytokines. As mentioned, a fraction of the caspase-1-cleaved IL-37 binds SMAD3 and translocates to the nucleus [19, 22] . SMAD-3 is responsible for most of the inhibitory and cytostatic effects of TGF-b. It is phosphorylated at its C-terminal MAD homology domain-1 (pSMAD3C) in response to TGF-b and exerts tumor suppressive effects. It can also be phosphorylated in its linker region (pSMAD-3L) by JNK in response to proinflammatory cytokines, such as IL-1b and TNF-a, and exerts fibrocarcinogenic effects [84] . An investigation into the nature of the cytokine binding with SMAD-3 would be highly desirable. Specifically, it would be interesting to see whether the cleaved cytokine can bind both pSMAD3C and pSMAD-3L and how that binding would affect the SMAD-3 effects on transcription. These studies could explain certain controversial aspects of the cytokine biology. For example, IL-37 exerts antiangiogenic effects in cancer [78] and proangiogenic ones in retinopathy [80] .
Because IL-37 inhibits both innate and adaptive immune responses, its expression by cancer cells may suggest they secrete it to dampen and escape the host's anticancer responses. So far, studies have examined only the expression of the cytokine by cancer cells and have not investigated whether they also secrete it. The secreted cytokine may act in both autocrine and paracrine manners to inhibit cancer growth. Supporting this notion are the observations made in various mouse models that loss of TIR-8 promotes cancer progression [63] [64] [65] . Cancer cells may escape the anticancer effects of the cytokine by down-regulating expression of its receptor, especially its signal-transducing subunit TIR-8. As mentioned, CRC escapes the anticancer effects of the cytokine by expressing the dominant, negative, exon 8-deleted splice variant of TIR-8 [30] . The variant is not only retained in the ER but also sequesters the normal wild-type protein into this compartment. These CRCs are unresponsive to exogenous IL-37. It would be necessary to restore expression of the cytokine receptor before using IL-37 as an immunotherapeutic tool in these cancers, although the cancer cells may still be responsive to the cytokine expressed inside the cytoplasm. Currently, little is known about the expression status of TIR-8 in other cancers, such as RCC, NSCLC, and OSCC, among others. It could be especially important to investigate whether these cancers express the exon 8-deleted variant of TIR-8. Furthermore, cancers may express nonfunctional isoforms of the cytokine. Further studies are required to understand the expression of different isoforms of IL-37 in cancers.
In addition to its anti-inflammatory and immune-deviatory effects, IL-37 also exerts metabolic effects. For example, it inhibits mTOR and activates AMPK, causing pseudostarvation [25] . The metabolic needs of cancer cells are quite different from those of healthy cells. Therefore, cancer cells reprogram their metabolic pathways. These pathways have been the focus of intensive research since the 1920s, when it was discovered that cancer cells increased the flux of glycolysis and produced lactic acid, famously known as the "Warburg effect" (reviewed in [85] ). Many strategies have been conceived and are underway to control cancer by targeting specific steps in these pathways [86] . It would be highly desirable to investigate how the cytokine modulates metabolic pathways and affects progression of cancer cells.
To our knowledge, all studies investigating the effects of IL-37 on cancers have been conducted using the IL-37b isoform. As mentioned, IL-37 exists in 5 isoforms resulting from alternate splicing of its primary RNA transcripts [15, 87] . Little is known about the expression and effects of other isoforms on the biology of cancer in humans. Future studies should address this issue. Furthermore, the protective role of IL-37/TIR-8 has been demonstrated in a variety of cancers. However, little is known concerning its effects on many other cancers, such as breast cancer, pancreatic cancer, leukemia, and glioblastoma, to mention a few.
IL-37 exerts a wide range of effects on both healthy and cancer cells. These effects seem to result from more than inactivating different components implicated in the signaling cascades initiated by TLRs or IL-1RF members. It is tempting to speculate that the cytokine may bind to other, unknown molecules/transcriptional regulators. There is still much to be learned about the immunobiology of this cytokine. Nevertheless, the anticancer effects of the cytokine reviewed here amply demonstrate the role of inflammation in the progression of cancer, which not only promotes growth and proliferation of cancer cells but also blunts anticancer immune responses. Paradoxically, IL-37 may promote anticancer immune responses by attenuating inflammation. This provocative hypothesis requires further investigations.
CONCLUSIONS
IL-37 is a member of the IL-1F that shows potent antiinflammatory effects. Despite its immune-deviating and immunosuppressive effects, it has a protective role in a variety of human cancers, including HCC, RCC, OSCC, NSCLC, and colorectal cancers, among others. In these cancers, the cytokine expression could be used as an important new prognostic biomarker as well as an immunotherapeutic tool. IL-37 is likely to have a similar host-protective role in other cancers, such as breast cancer, prostate cancer, leukemia, and glioblastoma, among others. In this regard, the cytokine represents a new hope for patients with cancer. We are only beginning to understand how the cytokine exerts its anticancer effects and how cancers may escape the cytokine's anticancer effects. Advances in these fundamental aspects of the cytokine will be crucial in turning this hope into a reality for patients with cancer. 
